Holding(s) in Company

RNS Number : 5012Q
Advanced Medical Solutions Grp PLC
19 October 2011

For immediate release: 19 October 2011 


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Holdings in company


AMS has been informed that following the disaggregation exemption notified to the FSA under the Disclosure and Transparency Rules on 17th October 2011, AXA SA and its subsidiary notifying Group entities, acting independently from their parent and from each other, no longer have any reportable holdings in Advanced Medical Solutions Group Plc on a Group aggregated basis. However, AXA Investment Managers SA has now crossed the 10% threshold and has a holding of 10.73% and 16,657,658 shares on a Group disaggregated basis as an independent Group subsidiary.




– ends –


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn



Notes to Editors:


About Advanced Medical Solutions Group plc – see www.admedsol.com


Advanced Medical Solutions Group is a global business providing innovative products and brands in the areas of accelerating healing and managing wounds, minimising adverse surgical outcomes and sealing and closing tissue. These products are sold in countries across the globe either directly or through a number of strategic partners and distributors.


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


This information is provided by RNS
The company news service from the London Stock Exchange